drugset / Trial / NCT04564716
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Phase 3
Unknown
100 enrolled
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
CRO: iPharma · collabRussian Direct Investment Fund · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults in the SARS-СoV-2 infection prophylactic treatment.
Timeline
- Start
- 2020-09-28
- Primary completion
- 2021-03-28
- Completion
- 2021-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gam-COVID-Vac | Vaccine | 0.5 ml | Intramuscular |